Mayne Pharma Group Limited (ASX: MYX) has announced the commercial launch of MICROGESTIN 24 FE to customers in the US.
MICROGESTIN 24 FE tablets are a generic version of LOESTRIN 24 FE tablets indicated for the prevention of pregnancy.
According to IQVIA, the annual US market sales of the generic equivalents were approximately US$75 million for the 12 months ended October 2020.
We are very pleased to launch MICROGESTIN 24 FE which complements our existing women’s health portfolio of branded generic contraceptives,” Mayne Pharma’s CEO Scott Richards said.
“As one of the leading suppliers of oral contraceptives in the US, we continue to focus on expanding our portfolio with novel and generic products.
“Mayne Pharma expects to launch up to seven new contraceptive products over the coming year including the novel oral contraceptive NEXTSTELLISTM (E4/DRSP), a generic version of NUVARING and a further five generic products.
“Mayne Pharma’s women’s health portfolio includes 27 marketed and pipeline products which cover more than 85% of US oral contraceptive prescription volumes.
MICROGESTIN 24 FE is the first of five anticipated new product launches sourced from the recently announced strategic partnership with Novast Laboratories.”
MICROGESTIN 24 FE is indicated for use by women to prevent pregnancy.
Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptive (COC) use.
This risk increases with age, particularly in over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke.
Oral contraceptives should not be used in women who currently have the following conditions: